PCVX
Vaxcyte, Inc.
56.63
USD
This page is just a preview of the data found in TrendSpider’s full version
Vaxcyte, Inc. stock is up 17.88% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 1 PUT, 1 CALL. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 27 Oct 17:21 | 17 Nov, 2023 | 45.00 | 30 | ||
| 17 Nov 15:47 | 19 Jan, 2024 | 55.00 | 10 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.
